Sanjay K. Juneja, MD, hematologist & medical oncologist at Mary Bird Perkins Cancer Center, discusses how artificial intelligence is transforming early cancer screening.

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, discussed the mechanism of action of amivantamab and the ...

The advent of cellular therapies, such as chimeric antigen receptor T-cell therapy, has revolutionized the field of ...

Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

Neoadjuvant chemotherapy's effect on local disease management of breast cancer has a number of clinical implications, including tumor downsizing, potentially improved overall survival, and more.

In separate, live events, Binod Dhakal, MD, MS; and Laahn H. Foster, MD, polled oncologists on therapeutic options for a ...

Based Roundtable® event, Andrew M. Brunner, MD, discussed dosing strategy for erythropoiesis-stimulating agents as well as ...

The FDA granted priority review to taletrectinib in ROS1-positive advanced NSCLC, with a target decision date of June 2025.

Chunhui Han, PhD, discusses the use of of Gallium 68 PSMA-11 in biology-guided radiotherapy and whether or not the ...

Mark Agulnik, MD, discusses the intricacies of desmoid tumors that can be recognized before starting treatment for patients.

Experts review the 5-year results of the phase 3 SEQUOIA trial evaluating treatment options for previously untreated chronic ...

Progression-free survival was superior with first-line maintenance of palbociclib in HR-positive, HER2-positive metastatic ...